The results evidenced that, in patients with T2D and CVD, GLP-1 RA reduced CV events independently of SGLT2i use (P for interaction = 0.7 for MACE in the post hoc analysis; the HRs for MACE in the meta-analysis were 0.78 [95% CI 0.49 to 1.24] with SGLT2i and 0.77 [95% CI 0.76 to 0.92] without SGLT2i, P for interaction = 0.95). This evidence concerns the gene GCG and type 2 diabetes mellitus.